Zipes and Jalife's Cardiac Electrophysiology

Current TOC; final to be done in summer 2019: Section 1 STRUCTURAL AND MOLECULAR BASES OF ION CHANNEL FUNCTION 1. Voltage-gated sodium channels and electrical excitability of the heart 2. Voltage-gated calcium 3. Voltage-gated potassium channels 4. Structural and molecular bases of cardiac inward rectifier potassium channel function 5. Mammalian calcium pumps in health and disease 6. Structural and molecular bases of sarcoplasmic reticulum ion channel function 7. Organellar ion channels and transporters 8. Molecular organization, gating, and function of connexin-based gap junction channels and hemichannels Section 2 BIOPHYSICS OF CARDIAC ION CHANNEL FUNCTION 9. Structure-function relations of heterotrimetric complexes of sodium channel a and ss subunits 10. Regulation of cardiac calcium channels 11. Inhibition of phosphoinositide 3-kinase and acquired long QT syndrome 12. Structural determinants and biophysical properties of hERG1 channel gating 13. Molecular regulation of cardiac inward rectifier potassium channels by pharmacologic agents 14. Cardiac stretch-activated channels and mechano-electric coupling 15. Biophysical properties of gap junctions 16. Excitation-contraction coupling Section 3 INTERMOLECULAR INTERACTIONS AND CARDIOMYOCYTE ELECTRICAL FUNCTION 17. Ion channel trafficking in the heart 18. Microdomain interactions of macromolecular complexes and regulation of the sodium channel nav1.5 19. Fibroblast growth factor homologous factors modulate cardiac calcium channels 20. Macromolecular complexes and cardiac potassium channels 21. Reciprocity of cardiac sodium and potassium channels in the control of excitability and arrhythmias 22. The intercalated disc: A molecular network that integrates electrical coupling, intercellular adhesion and cell excitability 23. Function and dysfunction of ion channel membrane trafficking and post translational modification 24. Feedback mechanisms for cardiac-specific microRNAs and cAMP signaling in electrical remodeling Section 4 CELL BIOLOGY OF CARDIAC IMPULSE INITIATION AND PROPAGATION 25. Stem cell-derived nodal-like cardiomyocytes as a novel pharmacologic tool: Insights from sinoatrial node development and function 26. Gene therapy and biologic pacing 27. Intercellular communication and impulse propagation 28. Mechanisms of normal and dysfunctional sinoatrial nodal excitability and propagation 29. Cell biology of the specialized cardiac conduction system 30. Cardiac remodeling and regeneration Section 5 MODELS OF CARDIAC EXCITATION 31. Ionic mechanisms of atrial action potentials 32. Genetic algorithms to generate dynamical complexity electrophysiological models 33. Calcium signaling in cardiomyocyte dodels with realistic geometries 34. Theory of rotors and arrhythmias 35. Computational approaches for accurate rotor localization in the human atria 36. Modeling the aging heart Section 6 NEURAL CONTROL OF CARDIAC ELECTRICAL ACTIVITY 37. Innervation of the sinoatrial node 38. Mechanism for altered autonomic and oxidant regulation of cardiac sodium currents. 39. Pulmonary vein ganglia and the neural regulation of the heart rate 40. Neural activity and atrial tachyarrhythmias 41. Sympathetic innervation and cardiac arrhythmias Section 7 ARRHYTHMIA MECHANISMS 42. The molecular pathophysiology of atrial fibrillation 43. Myofibroblasts, cytokines, and persistent atrial fibrillation 44. Role of the autonomic nervous system in atrial fibrillation 45. Rotors in human atrial fibrillation 46. Body surface frequency-phase mapping of atrial fibrillation 47. Panoramic mapping of atrial fibrillation from the body surface 48. Mechanisms of human ventricular tachycardia and human ventricular fibrillation 49. Genetics of atrial fibrillation Section 8 MOLECULAR GENETICS AND PHARMACOGENOMICS 50. Mechanisms in heritable sodium channel diseases 51. Genetic, ionic, and cellular mechanisms underlying the J-wave syndromes 52. Inheritable potassium channel diseases 53. Inheritable phenotypes associated with altered intracellular calcium regulation Section 9 PHARMACOLOGIC, GENETIC, AND CELL THERAPY OF ION CHANNEL DYSFUNCTION 54. Pharmacologic bases of antiarrhythmic therapy 55. Pharmacogenomics of cardiac arrhythmias 56. Gene therapy to treat cardiac arrhythmias 57. Highly mature human iPSC-derived cardiomyocytes as models for cardiac electrophysiology and drug testing 58. Cardiac repair with human induced pluripotent stem cell-derived cardiovascular cells. Section 10 DIAGNOSTIC EVALUATION 59. Assessment of the patient with a cardiac arrhythmia 60. Electrocardiography of tachyarrhythmias: Differential diagnosis of narrow and wide QRS complex tachycardias 61. Electroanatomic mapping for arrhythmias 62. Computed tomography for electrophysiology 63. Magnetic resonance imaging for electrophysiology 64. Intracardiac echocardiography for electrophysiology 65. Exercise-induced arrhythmias 66. Cardiac monitoring: short- and long-term recording 67. Head-up tilt table testing 68. Autonomic regulation and cardiac risk 69. T-wave alternans 70. Noninvasive electrocardiographic imaging of human ventricular arrhythmias and Electrophysiological Substrate 71. Genetic testing Section 11 SUPRAVENTRICULAR TACHYARRHYTHIAS: MECHANISMS, CLINICAL FEATURES, AND MANAGEMENT 72. Sinus node abnormalities 73. Atrial tachycardia 74. Atrial tachycardia in adults with congenital heart disease 75. Typical and atypical atrial flutter: Mapping and ablation 76. Atrial fibrillation 77. Preexcitation, atrioventricular reentry, variants 78. Electrophysiological characteristics of atrioventricular nodal reentrant tachycardia: Implications for the rentrant circuits 79. Junctional tachycardia Section 12 VENTRICULAR TACHYCARRHYTHMIAS: MECHANISMS, CLNICAL FEATURES, AND MANAGEMENT 80. Premature ventricular complexes 81. Outflow tract ventricular tachycardias: Mechanisms, clinical features, and management 82. Fascicular ventricular arrhythmias 83. Bundle branch reentry tachycardia 84. Ischemic heart disease 85. Ventricular tachycardia in patients with dilated cardiomyopathy 86. Ventricular arrhythmias in hypertrophic cardiomyopathy 87. Ventricular tachycardias in arrhythmogenic right ventricular dysplasia/cardiomyopathy 88. VTs in catcholaminergic cardiomyopathy (catecholaminergic polymorphic ventricular tachycardia) 89. Ventricular arrhythmias in heart failure 90. Arrhythmias and conduction disturbances in non-compaction cardiomyopathy 91. Takotsubo cardiomyopathy 92. Brugada syndrome 93. Long and short QT syndromes 94. Anderson-Tawil syndrome 95. Timothy syndrome 96. J-wave syndromes 97. Idiopathic ventricular fibrillation 98. Sudden infant death syndrome 99. Sudden cardiac arrest/death in adults 100. Neurologic disorders 101. Drug-induced ventricular tachycardia 102. Ventricular arrhythmias in congenital heart disease Section 13 SYNCOPE AND BRADYARRHYTHMIAS 103. Syncope 104. Postural orthostatic tachycardia syndrome 105. Progressive conduction system disease 106. Atrioventricular block Section 14 ARRHYTHMIAS IN SPECIAL POPULATIONS PHARMACOLOGIC THERAPY 107. Sex differences in arrhythmias 108. Sudden cardiac death in athletes, including commotio cordis 109. Pediatric populations 110. Sleep-disordered breathing and arrhythmias 111. Ventricular assist devices and cardiac transplantation recipients Section 15 PHARMACOLOGIC THERAPY 112. Standard antiarrhythmic drugs 113. Innovations in antiarrhythmic drug therapy 114. Nontraditional drugs for sudden cardiac death 115. Prevention of stroke in atrial fibrillation: warfarin, anti-factor Xa and thrombin drugs Section 16 CARDIAC IMPLANTABLE ELECTRONIC DEVICES 116. Implantable cardioverter defibrillators: technical aspects 117. Implantable cardioverter defibrillators: clinical aspects 118. Subcutaneous implantable defibrillator 119. Implantable pacemakers 120. Cardiac resynchronization therapy 121. Newer applications of pacemakers 122. Remote monitoring Section 17 CATHETER ABLATION 123. Catheter ablation: Technical aspects 124. Catheter ablation: Clinical aspects 125. Ablation for atrial fibrillation 126. Ablation of supraventricular tachycardias 127. Catheter ablation for ventricular tachycardias with/without structural heart disease 128. Epicardial and other approaches 129. Ventricular fibrillation 130. Ablation in pediatrics 131. Congenital heart disease 132. Anesthesiology for EP procedures Section 18: SURGERY FOR ARRHYTHMIAS 133. Surgery for atrial fibrillation and other supraventricular tachycardias 134. Surgery for ventricular tachycardia Section 19 NEW APPROACHES 135. Cervical vagal stimulation for heart failure 136. Baroreflex stimulation 137. Spinal cord stimulation for heart failure and arrhythmias 138. Renal artery denervation 139. Left atrial appendage occlusion/ligation